Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.56 |
| ▸ | MAOA | P21397 | 6/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617536 | 0.83 | ITGB3 (0.63) | MAOBMAOAITGB3ITGA2BSRD5A1 | |
| SCHEMBL6468996 | 0.83 | MAOB (0.54) | MAOBMAOAITGB3ITGA2BSRD5A1 | |
| SCHEMBL3504992 | 0.76 | MAOB (0.56) | MAOBMAOAITGB3ITGA2BSRD5A1 | |
| SCHEMBL3504307 | 0.74 | MAOB (0.54) | MAOBMAOASRD5A1ARKCNH2 | |
| SCHEMBL6446421 | 0.74 | ITGB3 (0.57) | MAOBMAOAITGB3ITGA2BADAM17 | |
| SCHEMBL6470666 | 0.74 | ITGB3 (0.72) | MAOBMAOAITGB3ITGA2B | |
| SCHEMBL5638876 | 0.74 | MAOB (0.86) | MAOBMAOASRD5A1 | |
| SCHEMBL27543696 | 0.73 | MAOB (0.53) | MAOBMAOAITGB3ITGA2BSRD5A1 | |
| SCHEMBL5617941 | 0.73 | MAOB (0.53) | MAOBMAOAITGB3ITGA2BSRD5A1 | |
| SCHEMBL6440777 | 0.72 | MAOB (0.63) | MAOBMAOASRD5A1PTPN1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846832-B2 | 2,3-dihydro-isoindol-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040082603-A1 | 2,3-Dihydro-isoindol-1-one derivatives | HOFFMANN-LA ROCHE INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082603-A1 | 2,3-Dihydro-isoindol-1-one derivatives | MAOB, MAOA, COMT | MAOB 1/4885MAOA 2/4885ITGB3 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.